Sonoran Biosciences is a preclinical stage pharmaceutical company that has developed SB Gel, a novel viscous sustained release carrier. SB Gel enables sustained release of a wide variety of drugs to new sites in the body, including irregular surgical sites and device surfaces. We develop new formulations using approved active ingredients, requiring reduced development cost and risk while retaining the exclusivity of a typical pharmaceutical. Formulations based on SB Gel have potential in a number of therapeutic areas including infection and pain management. Our lead product, SBG002, is a fixed-dose combination of tobramycin and vancomycin being developed for treatment of prosthetic joint infection in a one-stage surgical approach.

About Us

Our Team

Sonoran Biosciences  |  1475 N. Scottsdale Rd. Suite 200  |  Scottsdale, AZ 85257  |  P: 480-389-6413

© 2018 Sonoran Biosciences, Inc.


Derek Overstreet, PhD: Co-Founder and Chief Executive Officer
Dr. Overstreet
manages Sonoran's intellectual property and oversees Sonoran's day-to-day research work. He has led efforts to raise over $1.8 million of non-dilutive funding for Sonoran through 3 NIH small business grants and led Sonoran's preparation for a Pre-IND meeting on SBG002. His research on novel hydrogels for biomedical applications has been presented at various conferences including meetings of the Musculoskeletal Infection Society, Orthopaedic Research Society, Materials Research Society, Biomedical Engineering Society, and the Society for Biomaterials.

Joseph Cooper,  MBA: Chief Business Officer
Mr. Cooper is an experienced pharmaceutical executive with a background in general management, corporate development, product development, and manufacturing. Mr. Cooper previously served as Executive Vice President for Medicis Pharmaceutical Corporation and in senior roles with Schein Pharmaceutical, Smith and Nephew, and GD Searle.
He is also President of Boulder Cove, LC, an operational and strategic consulting firm serving the pharmaceutical industry.

Alex McLaren, MD:
Co-Founder and Chief Medical Officer
Dr. McLaren
is one of a very small number of people that has expertise both in the biology of infection and orthopaedic surgery, with over 25 years of clinical experience focused on orthopaedic infections and an equal length of time in research related to antibiotic delivery. He is a past President and current Executive Board Member of the Musculoskeletal Infection Society (MSIS), the leading North American society of clinicians focused on bone and joint infection.

Brent Vernon, PhD: Co-Founder
Dr. Vernon is an Associate Professor of Biomedical Engineering at Arizona State University, having published over 40 peer-reviewed articles on injectable polymer-based biomaterials.

Ryan McLemore, PhD: Co-Founder
Dr. McLemore has authored over 20 peer-reviewed research manuscripts and 3 book chapters focused on orthopaedic biomaterials and drug delivery. He has held positions at Banner Health and Mayo Clinic.

Prosthetic joint infection (PJI) is a devastating complication of total joint replacement. PJI treatment requires multiple invasive surgeries staged months apart followed by a long recovery process and uncertain outcomes. Even when treated successfully, PJI can permanently alter a patient's life.


Likewise, the costs of PJI treatment are massive. There were nearly 50,000 PJIs treated in the US in 2014. With treatment of a single PJI imposing total costs of $100,000 or more, this represents a multi-billion dollar and growing burden on the healthcare system in the US alone. New reimbursement structures such as Accountable Care Organizations and bundled payments, shift the costs of managing infection to hospitals, strongly motivating providers to seek higher value treatments.


Despite urgent need, the current pipeline of new technologies to address PJI is virtually empty. Currently available products only facilitate the already expensive multi-surgery approach for the surgeon, and are often eschewed for a crude process involving hand-mixing of antibiotic powder into bone cement "off-label".


We are seeking not merely to facilitate treatment, but to enable an advancement in the standard of care for PJI: reliable treatment in a single surgery. Our lead product, SBG002, is designed to provide high and sustained antibiotic concentrations around the infected site which are sufficient to kill any remaining biofilm bacteria while being compatible with permanent reconstruction of the joint.

Prosthetic Joint Infection

Clinical Advisors

Antonia Chen, MD, MBA

Dr. Chen is an orthopaedic surgeon and is an Associate Professor at the Sidney Kimmel School of Medicine at Thomas Jefferson University. She is the current President of the Musculoskeletal Infection Society (MSIS) who recently accepted the position of head of Arthroplasty Research at Brigham and Women's Hospital in Boston, where she will focus on infection research. She has received multiple awards for clinical and basic science research focused on the diagnosis and management of prosthetic joint infection, and she completed an Adult Reconstruction fellowship at Rothman Institute. She has authored over 120 articles in peer-reviewed journals, several authoritative book chapters, and she has held administrative positions in a number of national and international societies.


Bryan Springer, MD

Dr. Springer is an orthopaedic surgeon, Associate Professor in the Department of Orthopedic Surgery at Carolinas Medical Center, Fellowship Director at OrthoCarolina, and a past President of MSIS. He has received national recognition from the Knee Society and AAHKS, and in 2014 was named one of the Top 22 North American Knee Surgeons by Orthopedics This Week. He is currently a member of both The Hip Society and The Knee Society and serves as Education Chair for AAHKS.  He has authored over 85 peer-reviewed articles, over 25 book chapters, and three textbooks focused primarily on complex total hip and knee replacement and infection.


Mark Spangehl, MD

Dr. Spangehl is an orthopaedic surgeon and educator. He is an Associate Professor at Mayo Clinic in Arizona and founded both the Orthopaedic Surgery Residency and Adult Reconstructive Surgery Fellowship at Mayo Clinic's campus in Phoenix, Arizona. He has over 15 years experience in clinical practice and research focused on total hip and knee replacement, including management of complications including postoperative pain and infection. He has published numerous peer-reviewed articles focused on diagnosis and management of prosthetic joint infection and postoperative pain management. Dr. Spangehl was contributor to the MSIS criteria for the diagnosis of prosthetic joint infection and has served in leadership roles for national orthopaedic societies in their activities related to prosthetic joint infection.